Ubs Oconnor LLC Viking Therapeutics, Inc. Call Options Transaction History

Ubs Oconnor LLC

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$49.84 - $70.47 $318,976 - $451,008	6,400 Added 47.06%	20,000 $1.27 Million
Q2 2024 Aug 14, 2024	SELL	$47.39 - $80.2 $1.72 Million - $2.92 Million	-36,400 Reduced 72.8%	13,600 $720,000
Q1 2024 May 15, 2024	BUY	$17.4 - $94.5 $869,999 - $4.73 Million	50,000 New	50,000 $4.1 Million

473

66.2M

5.72M

3.39M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $3.95B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.